Bravi Luca, Malinverno Matteo, Pisati Federica, Rudini Noemi, Cuttano Roberto, Pallini Roberto, Martini Maurizio, Larocca Luigi Maria, Locatelli Marco, Levi Vincenzo, Bertani Giulio Andrea, Dejana Elisabetta, Lampugnani Maria Grazia
From the New Strategies to Inhibit Tumor Angiogenesis Program Fondazione Italiana per la Ricerca sul Cancro (FIRC) Institute of Molecular Oncology Fondazione, Milan, Italy (L.B., M.M., F.P., N.R., R.C., E.D., M.G.L.); Institute of Neurosurgery (R.P.) and Department of Pathology (M.M., L.M.L.), Università Cattolica Sacro Cuore, Roma; Department of Surgery Division of Neurosurgery, U.O. Neurochirurgia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano (M.L., V.L., G.A.B.); Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden (E.D.); and Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research, Milan, Italy (M.G.L.).
Stroke. 2016 Mar;47(3):886-90. doi: 10.1161/STROKEAHA.115.011867. Epub 2016 Feb 2.
Cerebral cavernous malformation (CCM) is characterized by multiple lumen vascular malformations in the central nervous system that can cause neurological symptoms and brain hemorrhages. About 20% of CCM patients have an inherited form of the disease with ubiquitous loss-of-function mutation in any one of 3 genes CCM1, CCM2, and CCM3. The rest of patients develop sporadic vascular lesions histologically similar to those of the inherited form and likely mediated by a biallelic acquired mutation of CCM genes in the brain vasculature. However, the molecular phenotypic features of endothelial cells in CCM lesions in sporadic patients are still poorly described. This information is crucial for a targeted therapy.
We used immunofluorescence microscopy and immunohistochemistry to analyze the expression of endothelial-to-mesenchymal transition markers in the cavernoma of sporadic CCM patients in parallel with human familial cavernoma as a reference control.
We report here that endothelial cells, a cell type critically involved in CCM development, undergo endothelial-to-mesenchymal transition in the lesions of sporadic patients. This switch in endothelial phenotype has been described only in genetic CCM patients and in murine models of the disease. In addition, TGF-β/p-Smad- and β-catenin-dependent signaling pathways seem activated in sporadic cavernomas as in familial ones.
Our findings support the use of common therapeutic strategies for both sporadic and genetic CCM malformations.
脑海绵状血管畸形(CCM)的特征是中枢神经系统中存在多个腔隙性血管畸形,可导致神经症状和脑出血。约20%的CCM患者患有遗传性疾病,其CCM1、CCM2和CCM3这3个基因中的任何一个都存在普遍的功能丧失突变。其余患者发生散发性血管病变,其组织学特征与遗传性病变相似,可能由脑血管系统中CCM基因的双等位基因获得性突变介导。然而,散发性患者CCM病变中内皮细胞的分子表型特征仍描述甚少。这些信息对于靶向治疗至关重要。
我们使用免疫荧光显微镜和免疫组织化学方法,以人类家族性海绵状血管畸形作为参考对照,分析散发性CCM患者海绵状血管畸形中内皮-间充质转化标志物的表达情况。
我们在此报告,内皮细胞是CCM发展过程中的关键细胞类型,在散发性患者的病变中会发生内皮-间充质转化。这种内皮表型的转变仅在遗传性CCM患者和该疾病的小鼠模型中被描述过。此外,与家族性海绵状血管畸形一样,散发性海绵状血管畸形中TGF-β/p-Smad和β-连环蛋白依赖性信号通路似乎也被激活。
我们的研究结果支持对散发性和遗传性CCM畸形采用共同的治疗策略。